Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model

Saito, Tomiyoshi; Saitoh, Shu‐ichi; Asakura, Tsukasa; Kanke, Michito; Owada, Kenji; Maruyama, Yukio

doi:10.1016/0167-5273(93)90240-h

Cited by 11 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large number of publications report the use of thrombolytics in experimental arterial thrombosis models in dogs (LOE 3), but lack suitable controls thereby precluding their use to address the PICO question 26–86 . In most of these studies, thrombolytics were administered within 60 minutes of thrombosis, 10,18,26–29,31,33,34,36,39–41,45–58,61,64–69,73–76,78–82,84,85,87–94 with fewer studies investigating thrombolytics administered 90 minutes, 43,44,86,95 2 hours, 30,38,62,72,77 3 hours, 63,70 or 6 hours 96 after thrombosis.…”

Section: Resultsmentioning

confidence: 99%

“…Nonetheless, there was little consistency in findings across the studies supporting the PICO question precluding any conclusions supporting one drug over another. The vast majority of the experimental literature of arterial thrombolysis in dogs involved the use of rt‐PA and lacked comparisons with other commercially available thrombolytics 9,13,19,24,25,28–31,33,36,38–48,51,52,54,55,57–59,61,63,64,67–71,73,76,78–80,82–90,92–95,100–102 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

Sharp

Blais

Boyd

et al. 2022

J Vet Emergen Crit Care

View full text Add to dashboard Cite

ObjectivesTo systematically review available evidence and establish guidelines related to the use of thrombolytics for the management of small animals with suspected or confirmed thrombosis.DesignPICO (Population, Intervention, Control, and Outcome) questions were formulated, and worksheets completed as part of a standardized and systematic literature evaluation. The population of interest included dogs and cats (considered separately) and arterial and venous thrombosis. The interventions assessed were the use of thrombolytics, compared to no thrombolytics, with or without anticoagulants or antiplatelet agents. Specific protocols for recombinant tissue plasminogen activator were also evaluated. Outcomes assessed included efficacy and safety. Relevant articles were categorized according to level of evidence, quality, and as to whether they supported, were neutral to, or opposed the PICO questions. Conclusions from the PICO worksheets were used to draft guidelines, which were subsequently refined via Delphi surveys undertaken by the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) working group.ResultsFourteen PICO questions were developed, generating 14 guidelines. The majority of the literature addressing the PICO questions in dogs is experimental studies (level of evidence 3), thus providing insufficient evidence to determine if thrombolysis improves patient‐centered outcomes. In cats, literature was more limited and often neutral to the PICO questions, precluding strong evidence‐based recommendations for thrombolytic use. Rather, for both species, suggestions are made regarding considerations for when thrombolytic drugs may be considered, the combination of thrombolytics with anticoagulant or antiplatelet drugs, and the choice of thrombolytic agent.ConclusionsSubstantial additional research is needed to address the role of thrombolytics for the treatment of arterial and venous thrombosis in dogs and cats. Clinical trials with patient‐centered outcomes will be most valuable for addressing knowledge gaps in the field.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

Sharp

Blais

Boyd

et al. 2022

J Vet Emergen Crit Care

View full text Add to dashboard Cite

show abstract

“…Prostaglandin I 2 (IP) receptor agonists have demonstrated their potent antiplatelet and antithrombotic effects in experimental animals [10,11]. In addition, IP‐receptor agonists have been shown to reduce ischemic injury effectively in the acute myocardial infarction and stroke models [12–14].…”

mentioning

confidence: 99%

TRA-418, a novel compound having both thromboxane A2 receptor antagonistic and prostaglandin I2 receptor agonistic activities: its antiplatelet effects in human and animal platelets

Yamada

Miyamoto

Isogaya

et al. 2003

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Yamada N, Miyamoto M, Isogaya M, Suzuki M, Ikezawa S, Ohno M, Otake A, Umemura K. TRA-418, a novel compound having both thromboxane A 2 receptor antagonistic and prostaglandin I 2 receptor agonistic activities: its antiplatelet effects in human and animal platelets. Summary. TRA-418 is a novel compound that has been found in our screening for compounds having both thromboxane A 2 (TP) receptor antagonistic and prostaglandin I 2 (IP) receptor agonistic activities. In the binding assays, TRA-418 showed a 10-fold higher af®nity to TP-receptors than IP-receptors. TRA-418 inhibited platelet aggregation induced by the TP-receptor agonist, U-46619 and by arachidonic acid at concentrations lower than those required for inhibition of ADP-induced aggregations. Furthermore, TRA-418 inhibited not only platelet aggregation induced by ADP alone, but also that induced by ADP in the presence of the TP-receptor antagonist, SQ-29548. When the IC 50 values of TRA-418 for platelet aggregation were estimated in platelet preparations from monkeys, dogs, cats, and rats using ADP and arachidonic acid as the platelet stimulating agents, it was found that the values estimated in monkey platelets were quite similar to those estimated in human platelets. In ex vivo platelet aggregation in monkeys, TRA-418 exhibited signi®cant inhibitory effects on arachidonic acidinduced aggregation in platelet preparations from monkeys treated at 3 mg kg min À1 or higher doses, where neither a signi®cant decrease in blood pressure nor a signi®cant increase in heart rate was observed. These results are consistent with the fact that TRA-418 has a relatively potent TP-receptor antagonistic activity together with a relatively weak IP-receptor agonistic activity. Prostaglandin I 2 (IP) receptor agonists have demonstrated their potent antiplatelet and antithrombotic effects in experimental animals [10,11]. In addition, IP-receptor agonists have been shown to reduce ischemic injury effectively in the acute myocardial infarction and stroke models [12±14]. Despite these useful properties as antithrombotic agents, the clinical application of IP-receptor agonists have been limited to pulmonary hypertension or moderate thrombotic disease such as arterial sclerosis obstruction because of their potent vasodilating effects [15,16].In this connection, a number of in vitro studies have reported that remarkable synergistic effects on human platelet aggregation can be observed with concomitant use of an IP-receptor agonist and a TP-receptor antagonist [17±19]. This ®nding suggests a useful application of an IP-receptor agonist in combination with a TP-receptor antagonist in vivo. In fact, we have con®rmed that concomitant use of the IP-receptor agonist, beraprost, at a limited dose effectively potentiates the antithrombotic effects of aspirin and other TP-receptor antagonists without any severe hypotension [20]. These results prompted us to screen compounds having a relatively potent TP-receptor antagonistic activity together with a relatively weak IP-...

show abstract

Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina

Sakata

Hoshino

Yoshida

et al. 1995

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The purpose of this study was to investigate the effects of beraprost sodium, a stable prostacyclin analog, on the parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina. Thirty-one patients with exertional angina who had significant organic coronary artery stenosis in at least one of the three major coronary arteries were selected. All patients underwent quantitative exercise thallium-201 emission computed tomography before and 1 month after 120 micrograms per day of beraprost sodium administration. Before exercise, blood samples were collected from 8:30 a.m. to 9:30 a.m. after the patients had been lying in bed undisturbed for at least 10 minutes. Plasma platelet factor 4 (PF4), fibrinopeptide A (FPA), tissue plasminogen activator antigen (t-PA), and plasminogen activator inhibitor-1 activity (PAI-1) were measured. There were no significant differences in exercise parameters on both exercise tests. However, both the extent and severity scores of ischemia were significantly aggravated (p < 0.05 for both) during beraprost sodium administration. Plasma FPA levels decreased significantly during beraprost sodium administration (p < 0.01). Likewise, plasma PF4 levels decreased significantly during beraprost sodium administration (p < 0.05). As for plasma t-PA antigen levels, there was no significant difference before versus during beraprost sodium administration. Plasma PAI-1 activity levels decreased significantly during beraprost sodium administration (p < 0.05). The results indicate that beraprost sodium has strong antithrombogenic properties. However, its aggravation of myocardial ischemia may limit clinical usage.

show abstract

Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model

Cited by 11 publications

References 16 publications

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics

TRA-418, a novel compound having both thromboxane A2 receptor antagonistic and prostaglandin I2 receptor agonistic activities: its antiplatelet effects in human and animal platelets

Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina

Contact Info

Product

Resources

About